Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

September 17, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

April 28, 2011

Conditions
Crohn's Disease
Interventions
DRUG

Placebo

Placebo

DRUG

PROCHYMAL adult human mesenchymal stem cells

intravenous infusion four times over two weeks; possibly repeated once

Trial Locations (58)

10028

Weill Cornell Medical College, New York

10029

Mount Sinai School of Medicine, New York

11794

University Hospital and Medical Center, Stony Brook

14607

Rochester Institute for Digestive Diseases, Rochester

14621

Rochester General Hospital, Rochester

15212

Allegheney Center for Digestive Health, Pittsburgh

15213

University of Pittsburgh, Pittsburgh

20815

Metropolitan Gastroenterology Group, Chevy Chase

20892

National Institutes of Health, Bethesda

23249

McGuire Research Institute, Richmond

23502

Digestive and Liver Disease Specialists, Norfolk

27157

Wake Forest University, Winston-Salem

28207

Charlotte Gastroenterology and Hepatology, Charlotte

28734

Pinehurst Medical Clinic, Pinehurst

30342

Atlanta Gastroenterology Associates, Atlanta

32256

Borland-Groover Clinic, Jacksonville

32789

Shafran Gastroenterology Center, Winter Park

33162

Venture Research Institute, Miami

33765

Clinical Research of West Florida, Clearwater

37138

Gastroenterology Center of the Midsouth, Germantown

37205

Nashville GI Specialists, Nashville

37232

Vanderbilt University Medical Center, Nashville

40202

University of Louisville Hospital, Louisville

40536

University of Kentucky Hospital, Lexington

45415

Dayton Science Institute, Dayton

46202

Indiana University Medical Center, Indianapolis

48098

Center for Digestive Health, Troy

48124

Center for Clinical Studies, Dearborn

55455

University of Minnesota Hospital, Minneapolis

60637

University of Chicago Medical Center, Chicago

61801

Carle Clinic Association, Urbana

63128

St Louis Center for Clinical Studies, St Louis

66606

Cotton-O'Neil Clinical Research Center, Topeka

70808

Gulf Coast Research, Baton Rouge

74135

Gastroenterology United of Tulsa, Tulsa

74137

Options Health Research, Tulsa

75246

Baylor University Medical Center, Dallas

77030

Memorial Hermann Hospital, Houston

77555

University of Texas Medical Branch, Galveston

80033

Western States Clinical Research, Wheat Ridge

90033

University of Southern California University Hospital, Los Angeles

90822

Veteran's Administration Medical Center (does not require vet status), Long Beach

92801

Advanced Clinical Research Institute, Anaheim

94115

University of California, San Francisco, San Francisco

98133

Seattle Gastroenterology Associates, Seattle

06518

Gastroenterology Center of Connecticut, Hamden

02114

Massachusetts General Hospital, Boston

02115

Brigham and Womens Hospital, Boston

01610

Clinical Pharmacology Study Group, Worcester

03756

Dartmouth Hitchcock Medical Center, Lebanon

07927

Gastroenterology Research Associates, Cedar Knolls

07666

Holy Name Hospital, Teaneck

05401

University of Vermont, Burlington

T2N 4N1

University of Calgary, Calgary

T6G 2X8

University of Alberta Hospital, Edmonton

R3A 1R9

Health Sciences Centre, Winnipeg

N6A 5A5

London Health Sciences Centre, London

M5G 1X5

Mount Sinai Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mesoblast, Inc.

INDUSTRY

NCT00543374 - Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease | Biotech Hunter | Biotech Hunter